Pay in 4 interest-free payments of $5.56 Learn more
Ships within 48 hours · Estimated delivery Oct 21 - Oct 26
Petrelintide (ZP8396) Petrelintide (ZP8396) is a novel SC-administered, long-acting amylin analog, developed by Zealand Pharma (Sborg, Denmark), a peptide drug discovery and development company, which is currently in early-stage clinical trials (phase 1 clinical trials: ClinicalTrials.gov Identifier NCT05511025, NCT05096598 and NCT05613387) [116]
10.1016/j.bcp.2021.114817 141 ZhuH.CaiH.WangX.ChenT.ZhenC.ZhangZ.et al (2022)
The SUPRPASS-4 trial (262), involving 2002 participants with high-risk cardiovascular profiles followed for up to 104 weeks, showed no difference in 4-MACE events (cardiovascular death, myocardial infarction, stroke, and hospitalization for unstable angina) with tirzepatide compared to insulin glargine (HR 0.74
The medication cost effectiveness compared to bariatric surgery, the burden of obesity related healthcare costs in Canada, and real world evidence of long term benefit all factor into formulary decisions
Weight Loss and Reflux Symptoms An interesting aspect to consider is the role of weight loss, facilitated by higher doses of semaglutide, in the management of acid reflux
US$ 29.78
US$ 29.62
US$ 25.65
US$ 24.89
US$ 29.45
US$ 21.61
US$ 26.35
US$ 24.19
